CTOs on the Move

ArcherDX

www.archerdx.com

 
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.archerdx.com
  • 2477 55th Street Suite 202
    Boulder, CO USA 80301
  • Phone: 303.357.9001

Executives

Name Title Contact Details

Funding

ArcherDX raised $35M on 03/20/2018
ArcherDX raised $60M on 05/15/2019
ArcherDX raised $55M on 12/17/2019

Similar Companies

Nexstim

Founded in Finland in 2000, Nexstim is the world leader in Navigated Brain Stimulation (NBS) with image-guided Transcranial Magnetic Stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping. Nexstim initiated its two year multicenter clinical trial on the therapeutic effects of nTMS for stroke rehabilitation in June 2014 with Navigated Brain Therapy

Native Microbials

Northwest Biotherapeutics

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio`s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company`s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company`s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

NextImage Medical

NextImage Medical, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenBio

ormed in 1994, GenBio is an experienced, fully integrated medical diagnostic company focused on infectious disease and autoimmune disease diagnostics. GenBio develops, manufactures and markets extensive lines of infectious disease and autoimmunity